retatrutide clinical studies retatrutide for Sale in the US Eli Lilly infiltrates anti-obesity market

Hostetler More than 85% of obese participants with fatty liver disease in a clinical trial of the experimental drug retatrutide reduced their liver fat to the point where they would no longer be classified as having fatty liver disease, according to the Virginia Commonwealth University hepatologist leading the sub-study

Am I a good candidate

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

[1] Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations

Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes

FDA approval is expected in 2025-2026 if trials are successful